Traffic accidents leave nine people injured Nov 29, 2008
N.C. Highway Patrol reports are copied from SHP incident reports. Traffic charges are listed on those reports. (Rockingham Daily Journal, NC)
Courier names 28 Best Places to Work finalists Sep 18, 2008
Dunnhumby USA; Hobsons Inc.; Kendle International Inc.; McGohan Brabender; Microsoft Corp.; Modern Office Methods; Paycor Inc.; Phillips Edison & Co.; SHP Leading Design; St. Elizabeth Medical Center. Christ Hospital; The Deciding Factor; the Sheakley Group of Cos. (Cincinnati Business Courier, OH)
ADHD medication VYVANSE now available in 6 dosage strengths at US pharmacies Aug 27, 2008
Basingstoke, U.K. and Philadelphia, PA August 26, 2008 Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that VYVANSE is now available in U.S. pharmacies nationwide in three additional dosage strengths, bringing the total number to six: 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The expanded VYVANSE dosing options will allow physicians to individualize treatment for each patient. VYVANSE, which received FDA approval for the treatment of... (EurekAlert! -- Business News)
LETTERS: NCT, July 28, 2008 Jul 29, 2008
In mid-July, the research vessel Lance and the Swedish shp MV Stockholm got stuck in ice in the area and needed help from the Norwegian Coast Guard to get loose. The ice findings from the area spurred surprise among the researchers, many of whom expect the very North Pole to be ice-free by September this year. (North County Times)
First trust pilots NHS well-being scheme Jun 27, 2008
Secondary Navigation. Rotherham Primary Care Trust (PCT) has become the first of 10 sites to start testing a new approach to supporting the health and well-being of NHS staff. (SHPonline)
Long-term safety data on Lialda published in leading GI journal Jun 18, 2008
Basingstoke, UK and Philadelphia, US June 17, 2008 Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda (mesalamine). The primary endpoints of this study were to assess the safety and tolerability of Lialda in mild-to-moderate UC patients over 12 months. (EurekAlert!)
Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil May 27, 2008
First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide BASINGSTOKE, England and CAMBRIDGE, Massachusetts, May 27 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that ELAPRASE(R) (idursulfase), a human enzyme replacement therapy for the treatment of Hunter syndrome, has been approved by the Brazilian Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA). ELAPRASE, developed by... (PR Newswire)
Phase III pivotal results presented of VYVANSE to treat ADHD in adults May 9, 2008
WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints. "Adults with ADHD often find it challenging to focus and organize during the day. The disorder may impact many aspects of their lives from career... (EurekAlert!)
New analysis shows DAYTRANA offered ADHD symptom control for 12 months May 8, 2008
Washington, D.C. May 7, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD). The findings from the analysis reaffirmed that DAYTRANA has an established safety profile and effectively controlled ADHD symptoms... (EurekAlert!)
Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms May 8, 2008
WASHINGTON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD). (EurekAlert!)
FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults May 2, 2008
Basingstoke, U.K. and Philadelphia, PA April 23, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY,), the global specialty biopharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE (lisdexamfetamine dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. VYVANSE, introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years, is now the first and only once-daily prodrug... (EurekAlert! -- Business News)
Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting May 2, 2008
PHILADELPHIA May 1, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington,... (EurekAlert!)
Shire to Introduce a New UK Listed Holding Company Apr 15, 2008
BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, April 15 /PRNewswire-FirstCall/ -- THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND NOT A PROSPECTUS AND INVESTORS SHOULD NOT SUBSCRIBE FOR OR PURCHASE ANY SECURITIES REFERRED TO IN THIS ANNOUNCEMENT EXCEPT ON THE BASIS OF INFORMATION TO BE CONTAINED IN THE PROSPECTUS EXPECTED TO BE PUBLISHED BY SHIRE LIMITED IN CONNECTION WITH THE PROPOSED SCHEME. THE PROSPECTUS WILL BE PUBLISHED AND MADE AVAILABLE ON SHIRE'S WEBSITE AND WILL BE AVAILABLE FOR... (PR Newswire)
Opera previews Android browser Apr 11, 2008
Other mobile platforms that can run the browser include Symbian OS, Windows Mobile, Palm OS, BlackBerry OS, Samsung's SHP, and Motorola's P2K.. Add to. (InfoWorld)
Agency staff to get more protection Mar 20, 2008
Asked whether the EASI would be working more closely with the HSE, in the light of the crackdown, a spokesperson for BERR told SHP: The EASI works very closely with the HSE to coordinate investigations into agency wrongdoing. HSE will continue to lead investigations where health and safety is the central issue. (SHPonline)
Dedicate Valentine Day to People with HIV/AIDS Feb 12, 2008
The durbar was to offer a team from Safe Haven Project (SHP), a non-governmental organisation (NGO) based in the United States of America that was on a visit to educate people on HIV/AIDS, the platform to meet the people. The five-member team, which included people living with the virus, was in the country as guests of the Central Region AIDS Committee and Charles Aikins' Live and Let's Live Foundation, a local NGO. Mr David Butler, the Executive Director of Safe Haven Project and leader of the... (Ghana Web, Ghana)
First and Only Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis Now Available in Canada Jan 29, 2008
SAINT-LAURENT, QC, Jan. 29 /CNW/ - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the availability in Canada of MEZAVANT(R)(*) (mesalamine delayed and extended release tablets) with Multi Matrix System (MMX(TM)(xx)) Technology, indicated for the induction of clinical and endoscopic remission in patients with active, mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease. MEZAVANT is the first and only Health... (Canada Newswire)
Shire Completes FOSRENOL(R) Roll-Out in Major European Markets With Launch in Spain Jan 17, 2008
NOT FOR DISTRIBUTION IN THE UNITED STATES/ Non-Calcium Phosphate Binder for the Management of Hyperphosphataemia Now Available in 24 Countries BASINGSTOKE, England, Jan. 17 /CNW/ - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that with the launch today in Spain of FOSRENOL (lanthanum carbonate), a non-calcium phosphate binder, Shire is celebrating the completion of the launch roll-out in the major European markets. FOSRENOL is the first of the company's medicines developed in-house... (Canada Newswire)
FDA approves additional dosage strengths of Vyvanse Jan 4, 2008
PHILADELPHIA January 3, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for three additional dosage strengths for the attention deficit hyperactivity disorder (ADHD) treatment, VYVANSE (lisdexamfetamine dimesylate). Shire expects the three additional dosage strengths of 20 mg, 40 mg and 60 mg will be available in retail pharmacies in the second... (EurekAlert! -- Business News)
Notre Dame Baseball Completes Strong Eight-Player Fall Signee Class Dec 3, 2007
Pitcher Dustin Ispas headlines Notre Dame's 2008 signee class that includes three other talented lefthanded pitchers. Newcomers for the 2009 spring season will include four lefthanded pitchers, a righthander, two switch-hitting outfielders, and infielder Tommy Chase. (Und.com)
Parents survey: Perceptions of the duration of their child's ADHD medication Nov 12, 2007
Washington, DC November 9, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, yesterday announced results of a national survey where 60 percent of 121 mothers reported their 6 to12 year old childs once-daily Attention Deficit Hyperactivity Disorder (ADHD) medication stopped working before 6 p.m. The survey findings report the perceptions of 500 parents of children with ADHD regarding the duration of effectiveness of their childs once-daily... (EurekAlert!)
Gold and platinum help local market sparkle Oct 30, 2007
As most retailers extended gains, Shoprite (SHP) increased 55 cents, or 1. 39%, to R40. (Business Report, South Africa)
Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting Oct 27, 2007
73 BOSTON, Oct. 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced results from an analysis of VYVANSE(TM) (lisdexamfetamine dimesylate) effect size. These findings were presented today at a national meeting of psychiatrists in Boston. (PR Newswire)
VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment Oct 26, 2007
BOSTON October 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the results of a study which demonstrated that adults with Attention Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE (lisdexamfetamine dimesylate), the first prodrug stimulant. Findings from this phase III pivotal trial were presented today at a national... (EurekAlert!)
LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon Oct 18, 2007
Philadelphia, PA October 17, 2007 According to a study using a dynamic in vitro gastrointestinal tract system, Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis drug LIALDA (mesalamine) demonstrated a delivery system where the majority of the drugs active ingredient, 5-aminosalicyclic acid (5-ASA), is released over a prolonged period in the simulated colon. The colon is the site of inflammation in ulcerative colitis. (EurekAlert!)
Shire Divests Non-Core Product Portfolio to Almirall Oct 8, 2007
Reinforcing Strategic Focus on Growth-Driving Global Products BASINGSTOKE, England, October 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announces that it has agreed to sell a portfolio of non core products to Almirall for a cash consideration of $213m. The portfolio includes the dermatology products, SOLARAZE(R) (3% gel diclofenac sodium) and VANIQA(R) (eflornithine hydrochloride), and six other non-promoted products1... (PR Newswire)
FTSE 100 Declines: Northern Rock, Alliance & Leicester Lead the Retreat Sep 15, 2007
Shire Plc (SHP LN) declined 92 pence, or 7. 4 percent, to 1,154. (Bloomberg -- UK)
Addressing inmates' medical needs Aug 14, 2007
Brackett said the county has alerted medical care provider Southern Health Partners (SHP) that it is terminating its contract at the end of the month ... SHP is a primary provider for medical care for several county-operated jail in the South ... A primary reason, according to Brackett, is SHP's inability to provide inmates access to mental health services, as is required by North Carolina state law, including substance abuse treatment and counseling. (Lenoir News Topic, NC)
Shire's new ADHD medication, VYVANSE TM (lisdexamfetamine dimesylate) now available in US Jul 28, 2007
Philadelphia, PA July 27, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that VYVANSE TM(lisdexamfetamine dimesylate), a new once-daily medication approved to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD), is now available in U.S. pharmacies nationwide. In a clinical study, VYVANSE provided consistent ADHD symptom control throughout the day based upon parent reports in the morning (approximately 10am), afternoon (approximately 2pm), and early... (EurekAlert! -- Business News)
Shire announces filing of VYVANSE for treatment of ADHD in adults Jun 30, 2007
Philadelphia, PA June 29, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VYVANSE (lisdexamfetamine dimesylate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. This application is subject to a 10-month FDA review period. (EurekAlert! -- Business News)
Shire Demonstrates Commitment to Improving Patient Adherence in End Stage Renal Disease as New Phosphate-Binder FOSRENOL(R) Launches in Europe Jun 25, 2007
QUICK SEARCH BY ORGANIZATION. FREE SUBSCRIPTION SERVICES. (Canada Newswire)
Notre Dame Baseball Draft Recap And Updated Player Bios Jun 23, 2007
his impressive 2007 season at Seton Hall Prep - the nation's No. 1-ranked team - included an 11-0 record (setting the SHP record for wins in a season), 0 ... helped SHP win its third straight state title (10-1 over St. Joseph's) ... one of four players on the 2007 SHP team who signed with Division I programs (Porcello with North Carolina, Brooks with Wake Forest and rightfielder Nick Natale with Rice). (Und.com)
Shire Receives Approvable Letter From FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD Jun 21, 2007
BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, June 21 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an approvable letter from the US Food and Drug Administration (FDA) for INTUNIV (guanfacine) extended release tablets (previously referred to as SPD503), a nonstimulant selective alpha-2A-receptor agonist, which has been studied in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Unlike some other... (PR Newswire)
Shire In-Licenses JUVISTA(R) (Human TGFbeta3) From Renovo Jun 20, 2007
BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, June 20 /PRNewswire-FirstCall/ -- - Novel Biopharmaceutical Drug Candidate for the Prevention and Reduction of Scarring in Connection With Both Therapeutic and Cosmetic Surgery - a Market Served by Specialist Physicians - In-License Includes Exclusive Worldwide Rights Except for EU member States - Financial Payments Geared to Success and Linked to Significant Milestones - Renovo Estimates a Potential New Multi-Billion Market Opportunity in the... (PR Newswire)
HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes Jun 14, 2007
As part of the rebalancing, the following changes represent the additions and deletions to the Indexes: -- HealthShares(TM) Cancer Index added Shire PLC (ADR) (Nasdaq GS: SHPGY); and dropped Telik Inc. (Nasdaq GM: TELK). -- HealthShares(TM) Emerging Cancer Index added Telik Inc. (Nasdaq GM: TELK); and dropped Shire PLC (ADR) (Nasdaq GS: SHPGY) ... -- HealthShares(TM) European Drugs Index added Novo Nordisk A/S - B Shares (Copenhagen: NOVOB), KRKA (Ljubljana: KRKG), Grifols SA (Continuous: GRF);... (PR Newswire)
Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD May 24, 2007
SAN DIEGO May 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today announced that VYVANSE (lisdexamfetamine dimesylate) effectively controlled Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children aged 6 to 12 years. In addition, 95 percent of children taking VYVANSE daily for 12 months showed overall improvement, according to phase III open-label extension trial results. (EurekAlert!)
12-month study demonstrated tolerability and efficacy of Daytrana May 24, 2007
SAN DIEGO MAY 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that DAYTRANATM (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association (APA) annual meeting in San Diego. "We... (EurekAlert!)
Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms May 24, 2007
San Diego, US May 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today the positive results of studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term phase III placebo-controlled studies and two long-term phase III open-label studies, presented at the 2007 American Psychiatric Association (APA) annual meeting, demonstrated that GXR significantly... (EurekAlert!)
Ulcerative colitis remission rates from long-term safety study of LIALDA presented at DDW May 23, 2007
Washington, D.C. May 22, 2007 A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroenterology (BSG) meeting in Glasgow, Scotland in March 2007 showed Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) LIALDA (mesalamine) is well tolerated in mild to moderate UC patients. Today, secondary endpoints of study 303 were presented as post-hoc analyses at Digestive Disease Week (DDW). (EurekAlert!)
FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults May 20, 2007
BASINGSTOKE, United Kingdom, and PHILADELPHIA, May 19 /PRNewswire/ -- Shire plc (LSE: SHP; Nasdaq: SHPGY; TSX: SHQ) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for SPD465 (triple-bead mixed amphetamine salts [MAS], an investigational oral stimulant intended to provide symptom control of ADHD in adults for up to 16 hours with one daily dose. Following receipt of this approvable letter, Shire is evaluating its options related to... (PR Newswire)
DEA schedules VYVANSE, clearing way for launch of first prodrug stimulant ADHD treatment May 4, 2007
Basingstoke, U.K., Philadelphia, PA May 3, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Drug Enforcement Administration (DEA) has classified VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), as a Schedule II controlled substance, following the earlier recommendation of the U.S. Food and Drug Administration (FDA). The DEA schedule classification of VYVANSE represents the final step in the Federal government's administrative approval process... (EurekAlert! -- Business News)
Shire Plc Announces Refinancing of Bank Facilities Connected With the Recent Acquisition of New River Through the Launch of US$1,000 Million Convertible Bonds due 2014 to be Offered Outside the United States and to Non-US Persons Only May 2, 2007
This Announcement is not for Distribution or Release in Jersey, Canada and Japan or in any Other Jurisdiction in Which Offers or Sales Would be Prohibited by Applicable Law BASINGSTOKE, England, May 2 /PRNewswire-FirstCall/ -- Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces that it intends to make an offering of US$1,000 million principal amount of Convertible Bonds ("Bonds") due 2014 to international institutional investors outside the United States that are... (PR Newswire)
HealthShares(TM) Announces Change to the HealthShares(TM) European Drug Index Apr 14, 2007
NEW YORK, April 13 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard s, the calculating agent for the HealthShares(TM) European Drug Index, that effective at the opening of trading on Wednesday April 18, 2007, Solvay SA (SOLB-Brussels) and Shire PLC (SHP- London) will replace Actavis Group (ACT-Iceland) and AES Chemunex SA (AESCH- France) in the HealthShares(TM) European Drug Index.... (PR Newswire)
Steps for women's health Apr 6, 2007
But it was cheering to read that UHS now offers the new human papillomavirus (HPV) vaccine, Gardasil, and that the Student Health Plan (SHP) will cover 80 percent of the a fairly expensive course of three shots over six months ... It should try to find a way to cover the vaccine's entire cost for SHP subscribers and subsidize the vaccine even for women with private health insurance so that they too can be protected. (The Daily Princetonian, NJ)
FDA approval of Vyvanse as a novel treatment for ADHD Feb 25, 2007
Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). more. (SpiritIndia)
Neglected housing Feb 18, 2007
-based SHP Management, which bought the complex in 2002, said the inspection "is a snapshot of current property conditions" and that the company has made a number of improvements. Items identified as critical to the health and safety of residents were immediately corrected, Frost said. (The Clarion-Ledger)
FDA approves LIALDA (mesalamine) Jan 19, 2007
Basingstoke, UK and Philadelphia, US January 16, 2007 -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has approved LIALDATM(mesalamine) with MMX technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine. (EurekAlert! -- Business News)
India acquires first US-built warship Jan 18, 2007
Thursday, January 18, 2007. Indo-Asian News Service. (Hindustan Times, India)
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission Jan 11, 2007
BASINGSTOKE, England and CAMBRIDGE, Massachusetts, January 11 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announces today that the European Commission has granted a marketing authorisation for the use of ELAPRASE(R) (idursulfase) for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II or MPS II)(1). ELAPRASE is the first and only enzyme replacement therapy for people suffering from Hunter syndrome and it was launched in the U.S. in July... (PR Newswire)
